Overview

Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety and efficacy of lubiprostone administration in participants with opioid-induced bowel dysfunction.
Phase:
Phase 3
Details
Lead Sponsor:
Sucampo Pharma Americas, LLC
Sucampo Pharmaceuticals, Inc.
Collaborator:
Takeda
Treatments:
Lubiprostone